These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF-alpha stimulation. Okuda T; Nakakita S; Nakayama K Glycoconj J; 2010 Feb; 27(2):287-96. PubMed ID: 20082214 [TBL] [Abstract][Full Text] [Related]
67. Identification and characterization of the human Gb3/CD77 synthase gene promoter. Okuda T; Nakayama K Glycobiology; 2008 Dec; 18(12):1028-35. PubMed ID: 18757779 [TBL] [Abstract][Full Text] [Related]
68. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. Stricklett PK; Hughes AK; Ergonul Z; Kohan DE J Infect Dis; 2002 Oct; 186(7):976-82. PubMed ID: 12232838 [TBL] [Abstract][Full Text] [Related]
69. An in vitro model of Fabry disease. Shu L; Murphy HS; Cooling L; Shayman JA J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856 [TBL] [Abstract][Full Text] [Related]
70. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437 [TBL] [Abstract][Full Text] [Related]
71. A novel, promoter-based, target-specific assay identifies 2-deoxy-D-glucose as an inhibitor of globotriaosylceramide biosynthesis. Okuda T; Furukawa K; Nakayama K FEBS J; 2009 Sep; 276(18):5191-202. PubMed ID: 19674101 [TBL] [Abstract][Full Text] [Related]
72. Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research. Szymczak-Kulus K; Czerwinski M; Kaczmarek R Cell Mol Biol Lett; 2024 Nov; 29(1):137. PubMed ID: 39511480 [TBL] [Abstract][Full Text] [Related]